drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Genetically engineered autologous T cells expressing a CD19 chimeric antigen receptor with 4-1BB costimulation (second-generation) to target CD19+ B-ALL blasts; adoptive cellular immunotherapy that enhances T-cell activation, proliferation, persistence, and cytotoxic killing to eliminate residual disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a second-generation CD19-directed chimeric antigen receptor with 4-1BB costimulation. Upon binding CD19 on B-lineage blasts, CAR signaling (CD3 zeta with 4-1BB) activates the T cells, promoting expansion and persistence and mediating targeted cytotoxic killing of CD19-positive B-ALL cells.
drug_name
CD19-directed CAR-T cells
nct_id_drug_ref
NCT06481241